Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic iomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R. de Wit, C.Wülfing, D. Castellano, G. Kramer, J.-C. Eymar5, C. N. Sternberg, K. Fizazi, B. Tombal, A. Bamias, J. Carles, R. Iacovelli, B. Melichar, Á. Sverrisdóttir, C. Theodore, S. Feyerabend, C. Helissey, M. C. Foster, A. Ozatilgan, C. Geffriaud-Ricouard, J. de Bono
Исходное соотношение нейтрофилов к лим...